Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Karin Badel"'
Publikováno v:
Biology of Blood and Marrow Transplantation. 16(5):695-700
Rapid and durable recovery of hematopoietic function after hematopoietic stem cell transplantation (HSCT) requires the infusion of a sufficient number of hematopoietic stem cells (HSC). Granulocyte colony-stimulating factor (G-CSF), either alone or w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f77138e41f2c1fede828456b1324c73b
Publikováno v:
Biology of Blood and Marrow Transplantation. 16(1):95-101
Plerixafor is a selective antagonist of CXCR4 used for mobilization of hematopoietic stem cells (HSCs) for autologous stem cell transplantation (SCT) in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). This Phase 1 open-label study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c7eadd3a888b9d447fbe9ec4489e41
Autor:
Karin Badel, Ron MacFarland, Gary Calandra, John F. DiPersio, Feng Gao, Amanda F. Cashen, Sandra Lopez
Publikováno v:
Biology of Blood and Marrow Transplantation. 14(11):1253-1261
Collection of an adequate number of hematopoietic stem cells can be difficult in patients with relapsed or refractory Hodgkin lymphoma (HL) who are candidates for autologous stem cell transplantation (ASCT). Plerixafor (AMD3100), an inhibitor of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10703703bec9c62048a92cb9a91eb29
Autor:
Neal Flomenberg, Gary Calandra, David H. Vesole, Daniel J. Weisdorf, John F. DiPersio, Jane L. Liesveld, Steven M. Devine, Karin Badel
Publikováno v:
Journal of Clinical Oncology. 22:1095-1102
Purpose Interactions between the chemokine receptor CXCR4 and its ligand stromal derived factor-1 regulate hematopoietic stem-cell trafficking. AMD3100 is a CXCR4 antagonist that induces rapid mobilization of CD34+ cells in healthy volunteers. We per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06e9f5e2dfde096750be88ef2807d8e
https://doi.org/10.1200/jco.2004.07.131
https://doi.org/10.1200/jco.2004.07.131
Autor:
Gerhard Ehninger, S Müller, Julian Topaly, H. Goldschmidt, Stefan Fruehauf, A. D. Ho, Kai Hübel, G. Calandra, Marion Moos, Karin Badel
Publikováno v:
Bone marrow transplantation. 45(2)
This report describes the first investigational use of plerixafor in Europe and the determination of tumor cell mobilization by polymerase chain-reaction after plerixafor treatment in a subset of patients with multiple myeloma (MM). Thirty-five patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9be2d5e35c2d8fe4e27621707222d94
https://pubmed.ncbi.nlm.nih.gov/19597422
https://pubmed.ncbi.nlm.nih.gov/19597422
Autor:
C Dehner, A P Nademanee, Karin Badel, C Gibney, Gary Bridger, Richard T. Maziarz, Jane L. Liesveld, G. Calandra, Michael J. Dugan, William I. Bensinger
Publikováno v:
Bone marrow transplantation. 45(1)
Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb2366c12e49be94525fb627df5f5ec
https://pubmed.ncbi.nlm.nih.gov/19483760
https://pubmed.ncbi.nlm.nih.gov/19483760
Autor:
G. Calandra, Dye A, Joseph McGuirk, Guido Tricot, John M. McCarty, S.-A. Crocker, Grove B, Gary Bridger, Karin Badel
Publikováno v:
Bone marrow transplantation. 41(4)
AMD3100 given with G-CSF has been shown to mobilize CD34+ cells in non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and Hodgkin's disease (HD) patients who could not collect sufficient cells for autologous transplant following other mobilization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098da103565e0c57c51bce95ed8ee008
https://pubmed.ncbi.nlm.nih.gov/17994119
https://pubmed.ncbi.nlm.nih.gov/17994119
Publikováno v:
Stem cells and development. 16(4)
AMD3100 is a drug capable of mobilizing peripheral blood stem cells (PBSCs) in donors and in cancer patients as a single agent or in combination with granulocyte-colony-stimulating factor (G-CSF). We initiated a phase II study of 11 refractory or rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c84125d0642ef639978abe5429fb9208
https://pubmed.ncbi.nlm.nih.gov/17784839
https://pubmed.ncbi.nlm.nih.gov/17784839
Autor:
Karin Badel, Jane L. Liesveld, John M. McCarty, Scott D. Rowley, Neal Flomenberg, Gary Calandra, David H. Vesole, Steven M. Devine, John F. DiPersio
Publikováno v:
Blood. 106(5)
Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the trophic effects of the chemokine stromal cell-derived factor-1alpha (SDF-1alpha) binding to its receptor, CXC chemokine receptor 4 (CXCR4). AMD3100 reversibly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e5ca0b9fb72e06535ca347df126b69
https://pubmed.ncbi.nlm.nih.gov/15890685
https://pubmed.ncbi.nlm.nih.gov/15890685
Autor:
Jeffrey Christensen, David C. Dale, Christine Dehner, Brent L. Wood, Elin Rodger, Gary Calandra, Karin Badel, Thomas H. Price, Hal E. Broxmeyer, W. Conrad Liles
Publikováno v:
Transfusion. 45(3)
BACKGROUND: AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects. STUDY DESIGN AND METHODS: To further investigate potential clinical utility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f817054b89324da1bb4219a60a33ab
https://pubmed.ncbi.nlm.nih.gov/15752146
https://pubmed.ncbi.nlm.nih.gov/15752146